Skip to Content
Merck
All Photos(1)

Key Documents

View All Documentation

SML3236

Sigma-Aldrich

UNC10201652

≥98 mg/mL (HPLC)

Synonym(s):

4-(8-(piperazin-1-yl)-1,2,3,4-tetrahydro-[1,2,3]triazino[4′,5′:4,5]thieno[2,3-c]isoquinolin-5-yl)morpholine, 1,2,3,4-Tetrahydro-5-(4-morpholinyl)-8-(1-piperazinyl)[1,2,3]triazino[4′,5′:4,5]thieno[2,3-c]isoquinoline

Sign Into View Organizational & Contract Pricing
All Photos(1)

About This Item

Empirical Formula (Hill Notation):
C20H25N7OS
CAS Number:
372495-52-8
Molecular Weight:
411.52
UNSPSC Code:
12352107
NACRES:
NA.77

form

powder

Quality Level

100

concentration

≥98 mg/mL (HPLC)

color

white to beige

solubility

DMSO: 2 mg/mL, clear

storage temp.

2-8°C

SMILES string

C12=C(N3CCOCC3)N=C(SC4=C5N=NN=C4N6CCNCC6)C5=C1CCCC2

General description

UNC10201652 is a potent and substrate-dependent slow-binding inhibitor of bacterial β-glucuronidases (GUSs) in the gut. UNC10201652 appears to target a catalytic intermediate. It alleviates irinotecan-induced gut damage in mouse models of cancer.

Storage Class Code

11 - Combustible Solids

WGK

WGK 3

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable

Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Kristen A Biernat et al.
Scientific reports, 9(1), 825-825 (2019-01-31)
Bacterial β-glucuronidase (GUS) enzymes cause drug toxicity by reversing Phase II glucuronidation in the gastrointestinal tract. While many human gut microbial GUS enzymes have been examined with model glucuronide substrates like p-nitrophenol-β-D-glucuronide (pNPG), the GUS orthologs that are most efficient
Aadra P Bhatt et al.
Proceedings of the National Academy of Sciences of the United States of America, 117(13), 7374-7381 (2020-03-15)
Irinotecan treats a range of solid tumors, but its effectiveness is severely limited by gastrointestinal (GI) tract toxicity caused by gut bacterial β-glucuronidase (GUS) enzymes. Targeted bacterial GUS inhibitors have been shown to partially alleviate irinotecan-induced GI tract damage and
Samuel J Pellock et al.
ACS central science, 4(7), 868-879 (2018-08-01)
Microbial β-glucuronidases (GUSs) cause severe gut toxicities that limit the efficacy of cancer drugs and other therapeutics. Selective inhibitors of bacterial GUS have been shown to alleviate these side effects. Using structural and chemical biology, mass spectrometry, and cell-based assays

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service